SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

DYN

Dyne Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming data presentations at the MDA Conference (March 8–11, 2026) and the Q2 2026 BLA submission for z-rostudirsen as key catalysts. The strong cash runway reduces near-term dilution risk despite high burn.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.15
T+0 close · Mar 2, 2026 · via day close
Latest settled
+12.38%
T+60 · $18.15
Vs SPY
+3.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $16.15entry
  2. T+1 · 9mo ago −9.60%α −8.68% · $14.60
  3. T+5 · 8mo ago +9.54%α +10.74% · $17.69
  4. T+20 · 8mo ago +5.82%α +13.76% · $17.09
  5. T+60 · 6mo ago +12.38%α +3.06% · $18.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, showing statistically significant dystrophin expression and functional improvements. The company plans a Q2 2026 BLA submission for accelerated approval, with a potential U.S. launch in Q1 2027. Cash remains strong at $1.1 billion, supporting operations into Q1 2028, despite increased R&D and net losses.

Key Financial Metrics

EPS
$-3.47

Key Facts

  • Positive topline results from DELIVER trial: 5.46% normal dystrophin expression at 6 months (7-fold increase, p<0.0001); functional improvements in TTR and 10MWR vs. placebo (nominal p<0.05).
  • Z-rostudirsen safety profile remains favorable, with mostly mild-to-moderate treatment-related adverse events.
  • BLA submission for z-rostudirsen planned for Q2 2026; potential U.S. launch in Q1 2027 assuming Priority Review.
  • Enrollment in ACHIEVE trial for z-basivarsen in DM1 on track for completion in Q2 2026, with BLA submission expected in early Q3 2027.
  • Cash, cash equivalents, and marketable securities totaled $1.11 billion as of December 31, 2025, sufficient to fund operations into Q1 2028.
  • R&D expenses increased to $398.3 million in 2025 from $281.4 million in 2024; net loss widened to $446.2 million in 2025 from $317.4 million in 2024.

Financial Impact

Increased R&D spend of $116.9 million YoY and net loss expansion of $128.8 million reflect advancing clinical programs, offset by strong cash position of $1.11 billion.

cashr&dnet_loss

Risk Factors

  • Clinical trial results are not powered for statistical significance on functional endpoints; confirmatory Phase 3 trials are required.
  • Regulatory approval is not guaranteed, even with accelerated pathway plans.
  • Increased operating losses may pressure valuation if clinical milestones are delayed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247269

Track record

54 reports on DYN

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026